Metabolic signature might be an option to identify patients with early CP

Bálint Erőss, Andrea Szentesi, Peter Hegyi

Metabolites are biomarkers measured in blood, urine, stool and tissue samples, determined by several factors, most importantly by the gut microbiota and changes in the metabolism from chronic inflammation. It is often accompanied by morphological changes of the pancreas detectable by various radiological methods. Notably, the diagnosis of established CP is rarely challenging. Therefore, assessing the cost/benefit ratio and the limited access to the methodology, it is very unlikely that this specific metabolomic profile will be routinely used to diagnose CP. However, the most exciting clinical question is how to identify patients who will develop CP when there are no detectable radiologic features, significant clinical symptoms or overt exocrine insufficiency. Patients with early CP could benefit from interventions, and the full-blown CP could be prevented or significantly delayed. Therefore, we propose that the metabolomic profiles of patients with early CP and a high risk for developing advanced CP are analysed. The question arises, which patient population would benefit the most from the metabolomic test?

Our study group just published an analysis of a small cohort in which patients with three or more acute pancreatitis episodes have a high probability of developing CP. Therefore, based on Adam et al’s study, we decided to retest our observation in a large international cohort of patients with acute pancreatitis (AP). Between 2012 and 2019, from 13 countries and 30 medical centres, 2461 patients were enrolled into the Acute Pancreatitis Registry initiated by the Hungarian Pancreatic Study Group. The AP diagnosis was defined according to the International Association of Pancreatology (IAP)/American Pancreatic Association (APA) guidelines. The analysed cohort was representative of the complete AP cohort. The proportion of mild, moderately severe and severe cases was 71.0%, 23.7% and 5.3%. Our data analysis showed that the proportion of patients developing CP is exponentially associated with the number of AP episodes (1.6%, 5.8% and 21% with 1, 2 and 3 AP episodes, respectively, table 1).

Therefore, we believe that patients with three or more AP episodes with no morphological changes would be the best candidates in a longitudinal clinical trial to test the hypothesis of whether this newly developed metabolic profile would be a good diagnostic tool to identify patients with early CP.

Table 1 The proportion of patients in percentages developing CP

<table>
<thead>
<tr>
<th>Number of acute pancreatitis episodes (n)</th>
<th>CP (n)</th>
<th>no-CP (n)</th>
<th>Percentage (%) of the patients developing CP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>28</td>
<td>1706</td>
<td>1.6</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>295</td>
<td>5.8</td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>83</td>
<td>21</td>
</tr>
<tr>
<td>4</td>
<td>21</td>
<td>47</td>
<td>30.9</td>
</tr>
<tr>
<td>5</td>
<td>15</td>
<td>22</td>
<td>40.5</td>
</tr>
<tr>
<td>6</td>
<td>14</td>
<td>12</td>
<td>53.8</td>
</tr>
<tr>
<td>7</td>
<td>10</td>
<td>9</td>
<td>52.6</td>
</tr>
<tr>
<td>8+</td>
<td>15</td>
<td>11</td>
<td>57.7</td>
</tr>
<tr>
<td>Total cases</td>
<td>143</td>
<td>2185</td>
<td>6.1</td>
</tr>
</tbody>
</table>

CP, chronic pancreatitis; no-CP, patients without chronic pancreatitis.

Contributors PH conceptualised the study, BE and AS extracted and analysed the data. PH, AS and BE interpreted the data. BE wrote the manuscript. BE, AS and PH reviewed and contributed to the manuscript before finalisation and submission.

Funding National Research funded the study, Development and Innovation Office (Nemzeti Kutatási, Fejelesztési és Innovációs Hivatal); grant number: OTKA K131996.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was approved by the National Public Health Centre (Nemzeti Népegészségügyi Központ), under the ID: 17787-8/2020/EUIG. All participants in this study provided written informed consent.

Provenance and peer review Not commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Erőss B, Szentesi A, Hegyi P. Gut 2021;1-7. doi:10.1136/gutjnl-2021-324206

Received 21 January 2021
Revised 6 February 2021
Accepted 7 February 2021

Medical School, Institute for Translational Medicine, Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary

Correspondence to Professor Peter Hegyi, Medical School, Institute for Translational Medicine, Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary; hegyi2009@gmail.com

Copyright 2021 BMJ Publishing Group Ltd. All rights reserved. For permission to reuse any element of this article, please go to: https://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES


